- Home
- NBIX vs RVTY Comparison
NBIX vs RVTY Comparison
Compare NBIX & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | RVTY |
|---|---|---|
| Founded | 1992 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 11.8B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | NBIX | RVTY |
|---|---|---|
| Price | $130.43 | $99.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 15 |
| Target Price | ★ $175.95 | $113.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 05-11-2026 | 04-26-2026 |
| Dividend Yield | N/A | ★ 0.29% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | 1.21 |
| Revenue | $161,626,000.00 | ★ $3,311,822,000.00 |
| Revenue This Year | $22.57 | $6.34 |
| Revenue Next Year | $9.56 | $5.10 |
| P/E Ratio | ★ $27.47 | $80.85 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $84.23 | $81.36 |
| 52 Week High | $160.18 | $120.39 |
Technical Indicators
Market Signals| Indicator | NBIX | RVTY |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 44.28 |
| Support Level | $122.14 | $93.94 |
| Resistance Level | $129.94 | $106.55 |
| Average True Range (ATR) | 4.39 | 4.15 |
| MACD | -0.72 | -1.07 |
| Stochastic Oscillator | 39.90 | 36.95 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.